Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  ACADIA Pharmaceuticals Inc.    ACAD

ACADIA PHARMACEUTICALS INC.

(ACAD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
54.42(c) 53.57(c) 53.31(c) 54.46(c) 53.66(c) Last
888 712 708 530 629 349 555 279 756 059 Volume
+2.43% -1.56% -0.49% +2.16% -1.47% Change
More quotes
Financials (USD)
Sales 2020 444 M - -
Net income 2020 -290 M - -
Net cash position 2020 427 M - -
P/E ratio 2020 -29,1x
Yield 2020 -
Sales 2021 677 M - -
Net income 2021 -154 M - -
Net cash position 2021 353 M - -
P/E ratio 2021 -54,3x
Yield 2021 -
Capitalization 8 531 M 8 531 M -
EV / Sales 2020 18,3x
EV / Sales 2021 12,1x
Nbr of Employees 580
Free-Float 99,6%
More Financials
Company
ACADIA Pharmaceuticals Inc. (ACADIA) is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines to address the medical needs in central nervous system disorders. The Company's lead product, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA’s developments are focused on... 
More about the company
Notations Surperformance© of ACADIA Pharmaceuticals Inc.
Trading Rating : Investor Rating :
More Ratings
All news about ACADIA PHARMACEUTICALS INC.
01/11ACADIA PHARMACEUTICALS : SMBC Nikko Initiates ACADIA Pharmaceuticals With Neutra..
MT
01/07RBC Capital Raises Price Targets on Seven Stocks, Lowers Targets on Four, Ahe..
MT
2020ACADIA PHARMACEUTICALS : Cantor Fitzgerald Adjusts ACADIA Pharmaceuticals' Price..
MT
2020ACADIA PHARMACEUTICALS : to Present at the 39th Annual J.P. Morgan Healthcare Co..
BU
2020ACADIA PHARMACEUTICALS : Morgan Stanley Adjusts ACADIA Pharmaceuticals PT to $60..
MT
2020ACADIA PHARMACEUTICALS : Mizuho Starts ACADIA Pharmaceuticals at Buy With $69 Pr..
MT
2020Raymond James Upgrades ACADIA Pharmaceuticals to Strong Buy From Outperform; ..
MT
2020WARREN BUFFETT : Warren Buffett's Berkshire Is Becoming Its Own Elephant Investm..
DJ
2020ACADIA PHARMACEUTICALS : to Present at the Stifel 2020 Virtual Healthcare Confer..
AQ
2020ACADIA PHARMACEUTICALS : to Present at the Stifel 2020 Virtual Healthcare Confer..
BU
2020Morgan Stanley Adjusts ACADIA Pharmaceuticals' Price Target to $58 From $57, ..
MT
2020ACADIA PHARMACEUTICALS : Reports Third Quarter 2020 Financial Results
AQ
2020ACADIA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDI..
AQ
2020ACADIA : 3Q Earnings Snapshot
AQ
2020Earnings Flash (ACAD) ACADIA PHARMACEUTICALS Reports Q3 Revenue $120.6M, vs. ..
MT
More news
News in other languages on ACADIA PHARMACEUTICALS INC.
2016ACADIA PHARMACEUTICALS : le Nuplazid bientôt disponible aux Etats-Unis
2016Les valeurs à suivre sur les marchés américains
2016Les valeurs à suivre sur les marchés américains
2014ACADIA PHARMACEUTICALS : reçoit la désignation de thérapie novatrice de la part ..
2014ACADIA PHARMACEUTICALS : erhält FDA-Bezeichnung „Breakthrough Therapy&ldqu..
More news
Analyst Recommendations on ACADIA PHARMACEUTICALS INC.
More recommendations
Chart ACADIA PHARMACEUTICALS INC.
Duration : Period :
ACADIA Pharmaceuticals Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACADIA PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Average target price 61,70 $
Last Close Price 53,66 $
Spread / Highest target 34,2%
Spread / Average Target 15,0%
Spread / Lowest Target -21,7%
EPS Revisions
Managers and Directors
NameTitle
Stephen R. Davis Chief Executive Officer & Director
Srdjan R. Stankovic President
Stephen R. Biggar Chairman
Elena H. Ridloff Chief Financial Officer & Executive Vice President
Eliseo Oreste Salinas Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ACADIA PHARMACEUTICALS INC.0.37%8 531
MODERNA, INC.24.10%51 304
LONZA GROUP AG2.46%48 618
CELLTRION, INC.-12.53%38 786
IQVIA HOLDINGS INC.4.81%36 004
SEAGEN INC.6.06%33 601